Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

  • Cappuyns, Sarah
  • Piqué-Gili, Marta
  • Esteban-Fabró, Roger
  • Philips, Gino
  • Balaseviciute, Ugne
  • Pinyol, Roser|||0000-0002-0288-6314
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Vandecaveye, Vincent
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Montironi, Carla|||0000-0002-1453-2193
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Peix, Judit
  • Zeitlhoefler, Marcus
  • Mesropian, Agavni
  • Huguet Pradell, Júlia
  • Haber, Philipp K
  • Figueiredo, Igor
  • Ioannou, Giorgio
  • Gonzalez Kozlova, Edgar
  • D'Alessio, Antonio
  • Mohr, Raphael
  • Meyer, Tim
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Marquardt, Jens U
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Edeline, Julien
  • Finkelmeier, Fabian
  • Trojan, Jorg
  • Galle, Peter R
  • Foerster, Friedrich
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Montal, Robert
  • Gnjatic, Sacha
  • Pinato, David James|||0000-0002-3529-0103
  • Heikenwälder, Mathias
  • Verslype, Chris
  • Van Cutsem, Eric|||0000-0002-6372-1230
  • Lambrechts, Diether
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Dekervel, Jeroen
  • Llovet, Josep M.|||0000-0003-0547-2667
The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define " Immune-competent " and " Angiogenesis-driven " molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a " Resistant" subset. Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (" Immune-competent" and " Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients (" Immune-competent" and " Angiogenesis-driven" vs. "Resistant") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.